Denver Investment Advisors LLC raised its position in Prothena Corporation PLC (NASDAQ:PRTA) by 6.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,470 shares of the biotechnology company’s stock after buying an additional 435 shares during the period. Denver Investment Advisors LLC’s holdings in Prothena Corporation PLC were worth $404,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Rhumbline Advisers raised its stake in shares of Prothena Corporation PLC by 6.9% in the second quarter. Rhumbline Advisers now owns 45,262 shares of the biotechnology company’s stock worth $2,450,000 after buying an additional 2,936 shares during the last quarter. Crescent Grove Advisors LLC acquired a new stake in shares of Prothena Corporation PLC during the second quarter worth $271,000. Schwab Charles Investment Management Inc. raised its stake in shares of Prothena Corporation PLC by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 163,681 shares of the biotechnology company’s stock worth $8,859,000 after buying an additional 9,824 shares during the last quarter. Sei Investments Co. acquired a new stake in shares of Prothena Corporation PLC during the second quarter worth $176,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Prothena Corporation PLC by 181.6% in the second quarter. Russell Investments Group Ltd. now owns 33,876 shares of the biotechnology company’s stock worth $1,834,000 after buying an additional 21,846 shares during the last quarter.

Shares of Prothena Corporation PLC (PRTA) opened at 54.59 on Monday. The stock’s market cap is $2.09 billion. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $69.53. The company has a 50-day moving average price of $60.67 and a 200-day moving average price of $55.21.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. The firm had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s quarterly revenue was up 7951.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.18) EPS. On average, analysts expect that Prothena Corporation PLC will post ($4.52) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Shares Bought by Denver Investment Advisors LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/21/prothena-corporation-plc-prta-shares-bought-by-denver-investment-advisors-llc.html.

A number of equities research analysts have recently weighed in on the company. Evercore ISI assumed coverage on Prothena Corporation PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $83.00 price target on the stock. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research note on Friday, August 11th. BidaskClub lowered Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC assumed coverage on Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 price target on the stock. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $77.58.

In related news, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $64.89, for a total transaction of $324,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $324,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total value of $203,385.00. Following the transaction, the director now owns 6,345 shares in the company, valued at approximately $368,707.95. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.